Clinical Trial Update: SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating SC0245 in combination with Irinotecan for relapsed extensive-stage small cell lung cancer is registered, with unknown current statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• SC0245

Snippet

Sponsor: Biocity Biopharmaceutics Co., Ltd. | Conditions: Small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN